Investors focused on the Medical space have likely heard of GW Pharmaceuticals (GWPH), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
GW Pharmaceuticals is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GWPH is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for GWPH's full-year earnings has moved 41.31% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, GWPH has moved about 22.90% on a year-to-date basis. In comparison, Medical companies have returned an average of -0.28%. This means that GW Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Breaking things down more, GWPH is a member of the Medical - Products industry, which includes 80 individual companies and currently sits at #75 in the Zacks Industry Rank. This group has gained an average of 14.69% so far this year, so GWPH is performing better in this area.
Investors with an interest in Medical stocks should continue to track GWPH. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research